You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: MANDALMED, INC. Topic: N/A
N/ASTTR Phase I 1999 Department of Health and Human Services
SBC: INTELLIGENT OPTICAL SYSTEMS, INC. Topic: NICHD
DESCRIPTION (provided by applicant): Congenital heart diseases (CHD) are the most common serious congenital anomalies and the leading cause of death due to birth defects. Clinical practice relying on physical examination of the newborn before discharge from the nursery often misses newborns with critical CHD (CCHD), which can lead to death or long-term morbidities. Using pulse oximetry (PO) can im ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: INTELLIGENT OPTICAL SYSTEMS, INC. Topic: CBD20AT001
Intelligent Optical Systems, Inc., in collaboration with Bowling Green State University, proposes to develop a field-rugged, eye-readable indicating spray solution that can immediately detect synthetic opioids over a large area of contamination (i.e., military vehicles, individual protective equipment, clandestine labs, etc.). The proposed chemosensor in a spray solution format will detect multipl ...STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense
SBC: PARABON NANOLABS, INC. Topic: NIAID
DESCRIPTION provided by applicant There is a critical need for a safe and effective vaccine against HIV Decades of work have been invested in understanding the immune response to infection and different approaches have been taken to develop vaccines that are effective in preventing and treating the disease While effective in animal models none have been as effective in humans The immune ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
A multitargeted nanocarrier inhibitor of undruggable transcription factors for treating castration resistant prostate cancerSBC: PARABON NANOLABS, INC. Topic: 102
Project Summary This project addresses the critical need for treatments of castration resistant prostate cancer (CRPC) by proposing to engineer and develop a novel, nanostructured pharmaceutical (P-TRIS5) which will target tumor cells and deliver two potent, synergistic therapeutics (an siRNA and a small molecule) to inhibit the androgen receptor and RUNX, two commonly implicated transcription fac ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercializationSBC: FELIX BIOTECHNOLOGY INC Topic: NIAID
ABSTRACT Antibiotic-resistant infections are a major public health threat in the U.S. and globally, with Pseudomonas aeruginosa (Pa) being one of the top pathogens of concern. Phage therapy is a promising approach to treat these infections, with benefits of species-targeted activity that spares the host microbiome, an ability to penetrate biofilms and kill metabolically-inactive persister cells, a ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health